Table 3

Number of triggers identified in stage 1 by the primary reviewers and number (%) of adverse events (AEs), preventability and level of harm identified after stage 2 by the secondary reviewers

	Team I	Team II	Team III	Team IV	Team V	Mean all teams	Mean teams I, II, III, V
Primary review
Triggers	73	85	95	40	29	64	71
Secondary review
Patients with AE	8 (16)	7 (14)	10 (20)	16 (32)	9 (18)	10 (20)	8.5 (17)
Number of confirmed AEs	11	9	11	33	9	14.6	10
AEs/1000 patient days	33.2	27.2	33.2	99.7	27.2	44.1	30.2
Preventable AEs	4 (36)	6 (67)	9 (82)	20 (61)	3 (33)	8.4 (58)	5.5 (55)
Level of harm E	8 (73)	4 (44)	4 (36)	14 (42)	3 (33)	6.6 (45)	4.8 (48)
Level of harm F	2 (18)	4 (44)	6 (55)	18 (55)	5 (56)	7 (48)	4.2 (42)
Level of harm G	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)	0.2 (1)	0.2 (2)
Level of harm H	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Level of harm I	1 (9)	1 (11)	1 (9)	0 (0)	1 (11)	0.8 (5)	1 (10)

National Coordinating Council for Medication Error Reporting and Prevention Index level of harm: E, temporary harm to the patient and required intervention; F, temporary harm to the patient and required initial or prolonged hospitalisation; G, permanent harm to the patient; H, required intervention necessary to sustain life; I, may have contributed to patient's death.